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Introduction
Endometrial cancer is the most common gynecologic
cancer, with an annual incidence in Western countries
of 15 to 20 per 100,000 [1]. In approximately 75% of
patients with adenocarcinoma of the endometrium, the
invasive neoplasm is confined to the uterus at diagno-
sis [1]. Due to the early symptoms of irregular vaginal
bleeding in this predominantly postmenopausal
population, the often localized nature of the disease,
and the generally high survival rate, many physicians
believe that adenocarcinoma of the endometrium is a
relatively benign disease.
The standard treatment for patients with stage I
endometrial cancer is surgery, consisting of peritoneal
lavage for cytology, total abdominal hysterectomy and
bilateral salpingo-oophorectomy, and dissection of
pelvic and aortic nodes. During surgery, the abdominal
organs, including the diaphragm, liver, omentum, and
pelvic and bowel peritoneal surfaces, should be careful-
ly inspected and palpated. The pathologic information
obtained provides an optimal basis for decisions about
and design of adjuvant therapy. The most significant
prognostic factors are tumor stage, histologic grade,
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and depth of myometrial invasion. Others are age,
histologic type, peritoneal cytology, vascular space
invasion, progesterone receptor activity, menopausal
stage, and uterine size. If risk factors are present, pelvic
radiotherapy (RT) is usually indicated to reduce the risk
of vaginal and pelvic relapse. However, the value of
postoperative RT in the treatment of patients with stage
I endometrial carcinoma is controversial due to a lack of
data from randomized studies and the low relapse rate.
Many retrospective analyses suggest a reduction in the
risk of locoregional relapse and an increase in disease-
free and overall survival rates after RT [1]. Several
authors report that results obtained with postoperative
external beam RT (EBRT) followed by brachytherapy
were similar to those using EBRT alone, with an increased
rate of complications after the combination [2–4].
Two randomized studies have been reported [1,5].
In one, 540 women with endometrial stage I cancer who
had received postoperative vaginal RT were randomly
assigned to additional pelvic RT or observation [5],
while in the other, 715 women were randomized to pel-
vic RT or no further treatment [1]. In the first study, al-
though pelvic RT reduced vaginal and pelvic recurrence
(2% vs 7%), more distant metastases were found in the
pelvic RT group (10% vs 5%), and 5-year survival was not
improved (89% vs 91%). Only the subgroup with grade
3 tumors with deep (≥ 50%) invasion showed both im-
proved local control and survival after additional pel-
vic RT. In the second study, 5-year actuarial locoregion-
al recurrence rates were 4% in the RT group and 14%
in the control group (p < 0.001). Actuarial 5-year over-
all survival rates were similar in the two groups (81%
vs 85%; p = 0.31). There were treatment-related
complications in 25% of the RT group and 6% of the
control group (p < 0.0001). Survival after relapse was
significantly better for patients in the control group
(p = 0.02). Multivariate analysis showed that for loco-
regional recurrence, RT and age below 60 years were
significant favorable prognostic factors.
The National Comprehensive Cancer Network
(NCCN) Practice Guidelines for Endometrial Cancer
version 2000 recommended observation, vaginal bra-
chytherapy (VBT), or pelvic RT with or without VBT as
adjuvant therapy for patients with stage IA grade 3,
stage IB grade 2, and stage IC grade 1 cancer [6]. For
patients with low-grade and superficially invasive di-
sease, VBT only was recommended, while for those with
high-grade disease and deeper myometrial infiltration,
treatment was vaginal RT and EBRT. However, the
NCCN Practice Guidelines version 2003 recommend
that adjuvant treatment for patients with stage IA grade
3, stage IB grade 2, and stage IC grade 1 should be
determined by the presence or absence of adverse risk
factors [6]. Adverse risk factors include advanced age,
lymphovascular invasion, tumor size, depth of invasion,
and involvement of the outer third of the uterus. If
adverse risk factors are not present, adjuvant treatment
should be observation only or VBT. If adverse risk
factors are present, adjuvant treatment should include
pelvic RT and/or VBT.
To better understand the potential risks and benefits
of adjuvant treatment for patients with intermediate-
risk stage IA grade 3, stage IB grade 2, and stage IC
grade 1 carcinoma, a retrospective review of all patients
treated for such endometrial cancers between 1980
and 2001 was undertaken. The outcome of adjuvant
treatment with postoperative pelvic RT or surgery alone
was determined by comparing locoregional control,
overall survival, and treatment-related morbidity.
Materials and Methods
Between January 1980 and December 2001, 72 patients
with endometrial carcinoma meeting the study criteria
were treated at Veterans General Hospital–Taipei. Retro-
spective review of patients’ charts gave the required
parameters. Patients with insufficient documentation,
inadequate surgery, or with miscellaneous clinical fac-
tors that did not meet the study criteria were excluded
from the study. Finally, a total of 55 patients were eligi-
ble for data analysis. Patients were excluded if they had
a history of double primary cancer or postoperative ad-
juvant chemotherapy only.
Pathologic slides were reviewed by a senior patho-
logist who recorded in detail all pathologic parameters,
including histologic subtype, cellular grade, tumor size,
and evidence of lymph vascular space invasion. All
patients were staged based on the 1988 International
Federation of Gynecology and Obstetrics (FIGO) system
[7].
Eligible patients were divided into two groups based
on the adjuvant treatment: the surgery-only and surgery-
plus-RT groups. The type of RT included VBT alone, VBT
plus pelvic EBRT, and pelvic EBRT alone, chosen by the
attending physician. The VBT dose was 20 Gy at 500
rads/week, and the pelvic EBRT dose ranged from 45
to 50 Gy at 200 rads/day. RT morbidity was defined
according to the Radiation Therapy Oncology Group
(RTOG)/European Organization for Research and Treat-
ment of Cancer (EORTC) scoring scheme [8].
Survival and locoregional control rates were com-
pared between the two groups with respect to prog-
nostic factors including age, depth of myometrial inva-
sion, cellular grade, tumor size, and concomitant medi-
cal disease (diabetes mellitus or hypertension). Addi-
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tionally, the morbidity of each treatment modality was
analyzed.
Statistical methods
The Chi-squared test (with Yate’s correction for 2 × 2
contingency table) or Fisher’s exact test were used in uni-
variate analysis of differences between patient groups.
Survival curves were created using the Kaplan-Meier
product-limit estimates method and compared using
the log-rank test. A p value of less than 0.05 was consi-
dered statistically significant.
Results
Of the 55 patients with intermediate risk factors, one
had stage IA grade 3 disease, 52 had stage IB grade
2, and two had stage IC grade 1. The median follow-up
time was 47 months (range, 1–171 months). The pa-
tients’ ages ranged from 34 to 82 years (median, 56
years). All surgical specimens were histologically pro-
ven to be endometrioid adenocarcinoma. There were 34
patients in the surgery-only group and 21 in the surgery-
plus-RT group. The study groups were well balanced for
age, histologic grade, and myometrial invasion (Table
1). In the surgery-plus-RT group, 11 patients received
VBT, four received EBRT, and six received both VBT
and EBRT. VBT consisted of high-dose-rate192 Ir to the
vaginal vault with insertions using a cylindrical applicator.
The reference point for dose prescription was 0.5 cm
from the surface of the applicators, and total VBT doses
ranged from 12 to 21 Gy. The EBRT technique consis-
ted of an anterior and posterior parallel pair in three
patients, and a four-field box technique in seven pa-
tients.
Among the 21 patients receiving adjuvant RT, 12
had RT-related morbidity. Thus, the incidence of mild
(grade 1 or 2) late RT-related morbidity was 57%. The
symptoms of late RT-related morbidity included diar-
rhea, abdominal cramps, constipation, rectal bleed-
ing, dysuria, stress urinary incontinence (SUI), vaginal
dryness, and vulva itching (Table 2). SUI and vaginal
dryness were the most common symptoms (8 patients,
67%) in grade 1 RT-related morbidity.
There was no statistically significant survival
difference between the surgery-only and surgery-plus-
RT groups (p = 0.5927) (Figure 1). The 5-year overall
survival rates were 97% and 95%, respectively. The 10-
year overall survival rate was the same, 96%. Univariate
analysis of prognostic factors showed that only hyper-
tension had a significant influence on overall survi-
val (p < 0.0344) (Figure 2). The 5-year overall survival
rate was 98% in patients without hypertension and
Table 1. Patient characteristics
Surgery only (n = 34) Surgery + RT (n = 21)
n (%) n (%)
Age
   < 60 yr 21 (62) 15 (71)
   ≥ 60 yr 13 (38) 16 (29)
Parity
   Nulliparous 14 (12) 11 (5)1
   Multiparous 30 (88) 20 (95)
Diabetes mellitus
   Yes 17 (21) 15 (24)
   No 27 (79) 16 (76)
Hypertension
   Yes 12 (35) 13 (14)
   No 22 (65) 18 (86)
Obesity
   Yes 13 (38) 17 (33)
   No 21 (62) 14 (67)
Stage
   IA grade 3 1 (3) 10 (0)1
   IB grade 2 33 (97) 19 (90)
   IC grade 1 0 (0) 12 (10)
Histology
   Favorable 134 (100) 121 (100)
   Unfavorable 0 (0) 0 (0)
Tumor size
   < 2 cm 25 (74) 17 (81)
   ≥ 2 cm 19 (26) 14 (19)
LVSI
   Yes 0 (0) 1 (5)
   No 134 (100) 20 (95)
RT = radiotherapy; LVSI = left ventricular systolic index.
93% in those with hypertension.
The overall recurrence rate was 3.6% (2/55), and
both these patients had recurrence within the first 2
years. One had local vaginal recurrence and the other
had left external iliac lymph node recurrence and lung
metastasis. The first patient initially received adjuvant
Table 2. Morbidity of radiation
n
Abdominal cramp 2
Constipation 3
Diarrhea 3
Dysuria/SUI 4
Rectal bleeding 1
Vaginal dryness 4
Vulva itching 3
SUI = stress urinary incontinence.
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VBT only. Vaginal recurrence was proven by colposcopic
biopsy 2 years later, when she received pelvic EBRT and
VBT. She was alive without recurrence for 4 years after
salvage treatment. The other patient initially received
Figure 2. (A) Overall survival rates and hypertension. (B) Overall survival rates and diabetes mellitus (DM). (C) Overall survival
rates and age. (D) Overall survival rates and tumor size.
EBRT after staging surgery, then three courses of chemo-
therapy with PEC (cisplatin, epirubicin and cyclophos-
phamide) due to lymph node recurrence and lung meta-
stasis 2 years later. This patient died within the same
year. In the intermediate-risk group, the pelvic control
rate in patients treated with surgery alone was 100%,
compared with 95.23% in patients treated with surgery
plus RT.
Discussion
The increasing incidence of endometrial carcinoma in
the West has led to much renewed interest in the study
and treatment of this disease over the last two decades.
The pattern of spread and relapse of the disease,
prognostic factors, relative effectiveness of adjuvant
treatment, and optimization of RT techniques are still
not fully understood. Many large series, such as that re-
ported by the Gynecological Oncology Group (GOG)
[9] and others [10,11], have identified major prognostic
factors for survival and local failure: age, histologic
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Figure 1. Survival rates of patients with endometrial cancer
after staging surgery only and with adjuvant radiotherapy (p =
0.52927).
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grade, depth of myometrial invasion, adnexal spread,
vascular space invasion, cervix/isthmus involvement, posi-
tive peritoneal cytology, and gross peritoneal disease
[12]. Classically, the factors that are most often cited
as prognostic of outcome in patients with endometrial
carcinoma include depth of myometrial penetration
and histologic grade. However, the survival rate of early
stage endometrial carcinoma is generally high with sur-
gery alone and surgery plus RT. By administering brachy-
therapy after hysterectomy, Eltabbakh et al obtained
a 97% 15-year survival rate [13]. Ackerman et al [14]
and Ayhan et al [15] reported 100% and 97% 5-year
survival, respectively, using brachytherapy after stag-
ing lymphadenectomy.
In our study, there was no statistically significant
difference in 5-year survival between the surgery-only
and surgery-plus-RT groups (97% vs 95%; p = 0.5927).
The use and type of adjuvant RT (VBT, pelvic EBRT, or
both) for intermediate-risk stage I endometrial carcino-
ma remains controversial. Two well-designed prospec-
tive randomized trials questioned the use of pelvic RT.
In GOG study 99, there was a difference in disease-
free survival at 2 years favoring pelvic RT, but no over-
all survival advantage was found [16]. In the study by
Creutzberg et al [17], although pelvic RT achieved
significantly better locoregional control (p < 0.001),
there was no overall survival benefit (p = 0.31).
The mode of adjuvant RT that should be given has
also been an issue of debate; both EBRT and VBT have
been used alone or in combination. Some investigators
have come out in favor of EBRT [18], while others favor
VBT [13], and still others endorse combined EBRT and
VBT.
In the Ayhan et al study (n = 196, stage I endometri-
al carcinoma), the overall recurrence rate was 2.6%
(5/196), 80% of which occurred within the first 2 years
[15]. In the high-risk group (stage IC or grade 3 tumors),
the pelvic control rate in patients treated with surgery
plus RT was 100%, compared with 92% in patients
treated with surgery alone [15]. In our study, the
recurrence rate was 3.6%, all in the first 2 years. The
pelvic control rate in the surgery-only group was 100%,
compared with 95.23% in the surgery-plus-RT group.
These results do not show the significantly better
locoregional control achieved with pelvic RT in a previous
prospective randomized study. This was partly because
of the small sample size and partly because many cases
were excluded from our study. We need longer-term
observation and follow-up to validate our results.
The most common symptoms of late RT-related
morbidity were SUI and vaginal dryness. As our study
and many previous studies all report similar results of
no significant overall survival advantage with adjuvant
RT, adjuvant RT in addition to complete staging surge-
ry is not recommended in intermediate-risk endometrial
cancer.
According to the newly updated algorithms of NCCN
version 2003, adjuvant treatment of patients with endo-
metrial cancer stage IA, IB, and IC should be deter-
mined by the presence or absence of adverse risk factors.
We analyzed our data to find which prognostic factors
influenced outcome in patients with intermediate-risk
endometrial cancer. Age (< 60 years, ≥ 60 years), tumor
size (< 2 cm, ≥ 2 cm), parity (nulliparous or multiparous),
lymphovascular invasion, diabetes mellitus, obesity,
and adjuvant RT had no effect. Only hypertension had
statistical influence on the overall survival rate (p <
0.0344). Due to the generally high survival rate and
low relapse rate in intermittent-risk endometrial cancer,
many physicians believe that endometrial cancer is a
relatively benign disease and requires lower-morbidity
treatment. RT may be reserved for recurrence.
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